Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024 J.M. Remes-Troche; E. Coss-Adame; M. Schmulson; K.R. García-Zermeño; M. Amieva-Balmori; R. Carmona-Sánchez; O. Gómez-Escudero; P.C. Gómez-Castaños; M.E. Icaza-Chávez; A. López-Colombo; E.C. Morel-Cerda; M.Á. Valdovinos-Díaz; L.R. Valdovinos-García; A.S. Villar-Chávez;

Transitioning from NAFLD to MAFLD to MASLD in the Mexican population B.A. Priego-Parra; R. Bernal-Reyes; M.E. Icaza-Chávez; S.E. Martínez-Vázquez; J.M. Remes-Troche;

Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD B.A. Priego-Parra; A. Triana-Romero; R. Bernal-Reyes; M.E. Icaza-Chávez; S.E. Martínez-Vázquez; M. Amieva-Balmori; A.D. Cano-Contreras; H. Vivanco-Cid; J.M. Remes-Troche;